![]() |
市场调查报告书
商品编码
1305938
HPV 检测和 PAP 检测市场 - 按检测类型、按技术(聚合酶链反应、液基细胞学、混合捕获、免疫诊断)、按最终用途及预测,2023 - 2032 年HPV Testing and PAP Test Market - By Test Type, By Technology, (Polymerase Chain Reaction, Liquid-based Cytology, Hybrid Capture, Immunodiagnostics), By End-use & forecast, 2023 - 2032 |
到 2032 年,全球 HPV 检测和 PAP 检测市场规模将大幅扩大。HPV 和 PAP 检测领域的最新进展将为该行业带来显著的增长机会。图像分析和人工智能方面的进步推动了用于子宫颈抹片检查解读的计算机辅助系统的发展。这些系统可以帮助病理学家突出显示异常细胞,从而提高筛查过程的准确性和效率。
全球人乳头瘤病毒检测和巴氏涂片检测市场总体上按检测项目、技术、最终用途和地区进行划分。
根据检测方法的不同,从 2023 年到 2032 年,联合检测领域的行业份额将以超过 16% 的复合年增长率增长。宫颈癌和人乳头瘤病毒相关性传播疾病发病率的上升增加了对联合检测的需求。根据美国癌症协会的数据,2023 年,仅在美国就将诊断出约 13,960 例新的侵袭性宫颈癌病例。与单独检测宫颈异常相比,联合检测具有更高的灵敏度。人乳头瘤病毒检测和巴氏涂片检测相结合,可提高高级别癌前病变和早期宫颈癌的检测率。
根据技术的不同,聚合酶链反应(PCR)领域的产业价值将在 2032 年前取得丰厚的收益。PCR 检测的灵敏度和特异性高,可准确检测和识别 HPV DNA,有利于细分市场的增长。此外,PCR 检测还能确定是否存在持续性 HPV 感染,这种感染被认为患宫颈癌的风险较高。人们对早期检测 HPV 感染的认识不断提高,这将进一步促进该细分市场的增长。
根据最终用途,到 2032 年,诊断中心细分市场的产值将大幅增长。由于这些机构拥有先进的技术和经济有效的治疗方法,越来越多的人倾向于选择诊断实验室,从而推动了该细分市场的增长。这些中心还能提供准确、早期的疾病诊断,从而增加了患者人数。诊断中心数量的激增将进一步为细分市场的增长创造有利可图的机会。
从地区角度来看,到 2032 年,亚太地区 HPV 检测和 PAP 检测市场规模将超过 25 亿美元。女性人口对宫颈癌的易感性激增,增加了该地区对 HPV 和 PAP 检测的需求。此外,该地区的扩张还可归因于医疗基础设施的不断扩大,以及各种模式的有利监管环境。根据 IBEF 预测,到 2025 年,印度医疗器械市场规模将达到 500 亿美元。
Global HPV Testing and PAP Test Market size will expand significantly through 2032. Recent advancements in HPV and PAP tests will create notable growth opportunities for the industry. Advances in image analysis and AI have led to the development of computer-assisted systems for Pap test interpretation. These systems can aid pathologists by highlighting abnormal cells, potentially improving the accuracy and efficiency of the screening process.
The overall global HPV testing and PAP test market is divided based on test, technology, end-use, and region.
Based on the test, industry share from the co-testing segment will grow at over 16% CAGR from 2023 to 2032. The rising prevalence of cervical cancer and HPV-related sexually transmitted diseases has increased the demand for co-testing. As per the American Cancer Society, in 2023, around 13,960 new invasive cervical cancer cases will be diagnosed in the U.S. alone. Co-testing provides higher sensitivity in detecting cervical abnormalities compared to either test alone. The combination of HPV testing and Pap testing improves the detection of high-grade precancerous lesions and early-stage cervical cancer.
Based on the technology, industry value from the polymerase chain reaction (PCR) segment will register lucrative gains through 2032. High sensitivity and specificity of PCR tests allow for the accurate detection and identification of HPV DNA, favoring segment growth. Moreover, PCR testing can identify the presence of persistent HPV infections, which are considered to have a higher risk of developing cervical cancer. Growing awareness about the early detection of HPV infection will further contribute to segment growth.
Based on the end use, industry value from the diagnostic centers segment will witness substantial gains through 2032. Growing preference towards diagnostic laboratories owing to the availability of advanced technologies and cost-effective treatment in these facilities is leading to segment growth. These centers also offer accurate and early disease diagnosis, which increases patient footfall. Surging number of diagnostic centers will further create lucrative opportunities for segment growth.
From the regional perspective, the Asia Pacific HPV testing and PAP test market size will reach over USD 2.5 billion by 2032. Surging female population base's susceptibility to cervical cancer has increased the need for HPV and PAP testing in the region. Moreover, regional expansion can also be attributed to expanding healthcare infrastructure, in line with favorable regulatory scenarios for modalities. As per IBEF, India's medical device market will reach USD 50 billion by 2025.